Drug Manufacturers Top Gainers: Zogenix (NASDAQ:ZGNX), Raptor Pharmaceutical (NASDAQ:RPTP), Retrophin (NASDAQ:RTRX), Echo Therapeutics (NASDAQ:ECTE)

Zogenix, Inc. (NASDAQ:ZGNX) filed a lawsuit in the U.S. District Court in Massachusetts requesting the court to grant a temporary restraining order against execution of the executive order recently announced by Governor Deval Patrick, which prohibits the prescribing and dispensing of the Company’s prescription pain product that was approved by the U.S. Food and Drug Administration (FDA). Zogenix, Inc. (NASDAQ:ZGNX) shares after opening at $2.36 moved to $2.63 on last trade day and at the end of the day closed at $2.59. Company price to sales ratio in past twelve months was calculated as 10.95 and price to cash ratio as 5.02. Zogenix, Inc. (NASDAQ:ZGNX) showed a negative weekly performance of -10.38%.

Raptor Pharmaceutical Corp. (NASDAQ:RPTP) reported a net loss of $69.4 million for the year ended December 31, 2013. Raptor Pharmaceutical Corp. (NASDAQ:RPTP) shares advanced 5.05% in last trading session and ended the day on $8.95. RPTP return on equity ratio is recorded as -252.30% and its return on assets is -74.40%. Raptor Pharmaceutical Corp. (NASDAQ:RPTP) yearly performance is 57.85%.

Retrophin (NASDAQ:RTRX) CEO Martin Shkreli acquired 8,000 shares of the company’s stock on the open market in a transaction dated Friday, April 4th. The shares were purchased at an average cost of $19.64 per share, for a total transaction of $157,120.00. Following the transaction, the chief executive officer now directly owns 2,982,680 shares of the company’s stock, valued at approximately $58,579,835. Retrophin Inc. (NASDAQ:RTRX) shares moved up 7.45% in last trading session and was closed at $19.33, while trading in range of $17.61 – $19.46. Retrophin Inc. (NASDAQ:RTRX) year to date (YTD) performance is 176.14%.

Echo Therapeutics Inc. (NASDAQ:ECTE) Philadelphia-based developer of transdermal skin permeation and diagnostic medical devices reported its fourth-quarter and full-year 2013 results on Mar 27. The fourth-quarter reported loss per share more than doubled year over year to $3.9 million or 36 cents. However, adjusted loss per share of 35 cents was narrower than the Zacks Consensus Estimate of a loss of 36 cents. Echo Therapeutics Inc. (NASDAQ:ECTE) weekly performance is 2.51%. On last trading day company shares ended up $3.27. Echo Therapeutics Inc. (NASDAQ:ECTE) distance from 50-day simple moving average (SMA50) is 3.38%. Analysts mean target price for the company is $6.50.